Ropinirole

Limits on what this shows

• Key negative/null findings: Parvez 2010 explicitly found ropinirole "does not impair normal mitochondrial respiration" at pore-blocking concentrations and showed no direct reactive-oxygen-species-scavenging activity itself, meaning the protective mechanism is structural pore-blockade, not direct antioxidant chemistry.
• At-risk subgroups: Not applicable; this is a protective animal-model finding, not a human risk signal.
• Counter-evidence: No source identified suggests mitochondrial harm from ropinirole at any evidence tier.

Regulatory status

No mitochondrial toxicity signal is listed in FDA labeling.

Population evidence

None in humans. Parvez et al 2010: isolated rat liver and brain mitochondria/mitoplasts, patch-clamp and swelling assays. Andrabi et al 2020: Wistar rats, transient middle-cerebral-artery occlusion (stroke) model, ropinirole 10-20 mg/kg subcutaneously post-occlusion.

Mechanism

Ropinirole acts as a lipophilic cation that directly blocks permeability-transition-pore opening (IC50 3.4 µM by patch-clamp, 50 µM by swelling assay), reversibly and comparably to cyclosporin A. In the stroke model, ropinirole preserved mitochondrial membrane potential and inhibited cytochrome c release, reducing infarct size and improving motor recovery.

Counter-evidence held on record

Both supporting studies use supra-clinical injury models (cell-free mitochondria, ischemia/reperfusion) rather than ordinary Parkinson's or RLS patients at labeled oral doses. This should not be read as ropinirole "protecting mitochondria" in routine use, only that no burden signal exists and the mechanistic direction found is protective.

Limits on what this shows

• Key negative/null findings: Iida 1999 found in vitro direct radical-scavenging activity "very weak," meaning the in vivo antioxidant-enzyme effect is receptor-mediated signaling, not a direct chemical antioxidant action; this is a mechanistic limitation, not a null result on the endpoint itself.
• At-risk subgroups: None identified; findings are protective/mechanistic only.
• Counter-evidence: No source identified shows ropinirole increasing oxidative-stress markers in any species.

Regulatory status

Not addressed in FDA labeling.

Population evidence

None in humans. Iida et al 1999: mice, 6-hydroxydopamine striatal dopaminergic-lesion model, 7-day ropinirole pretreatment. Selva & Srinivasan 2016: cell-free DPPH free-radical-scavenging assay.

Mechanism

Iida 1999: ropinirole increased striatal glutathione, catalase, and superoxide dismutase activity and protected dopaminergic neurons from 6-OHDA toxicity; pretreatment with the D2 antagonist sulpiride blocked this effect, confirming a D2-receptor-mediated (not direct chemical) mechanism. Selva & Srinivasan 2016: ropinirole showed dose-dependent DPPH-scavenging activity, 78.4% inhibition at 50 µg/mL (IC50 16.3 µg/mL) versus ascorbic acid's 89.3% (IC50 10.2 µg/mL).

Counter-evidence held on record

Both studies are animal or cell-free; neither should be read as clinical evidence that ropinirole treats or prevents oxidative-stress-related disease in patients, or as license to claim an "antioxidant benefit" on a consumer-facing page.

Limits on what this shows

• Key negative/null findings: Morgan 2008's explicit null finding, that baseline ferritin does not predict ropinirole's efficacy, argues against an iron-corrective or iron-mediated mechanism of action for the drug itself.
• At-risk subgroups: RLS patients with pre-existing low ferritin (commonly referenced clinical threshold: consider iron status when ferritin is under 75 ng/mL) carry higher augmentation risk during long-term dopamine-agonist therapy, per Trenkwalder et al 2008 (cabergoline/levodopa cohort, not ropinirole) and the Zeng et al 2023 synthesis review. This reflects the disease/risk-marker relationship, not a ropinirole-caused iron effect.
• Counter-evidence: The FDA-label "anemia" AE term (2% vs 0%, advanced Parkinson's) is disclosed as an unresolved, low-confidence signal: it is a single table entry with no stated mechanism, no ferritin/iron-study confirmation, and no replication in the RLS trials or the mechanistic literature reviewed here.

Regulatory status

Iron, ferritin, and anemia are not defined adverse-reaction categories for ropinirole. A single "anemia" adverse-event term appears at 2% (ropinirole) vs 0% (placebo) in advanced-Parkinson's trials (FDA label §6.1, Table 4), unaccompanied by any lab confirmation or mechanism.

Population evidence

Morgan, Ames & Sethi 2008 (ropinirole-specific RLS cohort): "Response to ropinirole in restless legs syndrome is independent of baseline serum ferritin." García-Borreguero et al 2012 (ropinirole-specific, 404 patients, 66-week prospective trial): augmentation incidence about 3.1 percentage points higher with ropinirole than placebo; ferritin was not reported as a covariate.

Mechanism

No mechanism is established for ropinirole lowering iron stores. The class-level literature (not ropinirole-specific) frames the relationship the other way: iron is a cofactor for tyrosine hydroxylase, so pre-existing low iron impairs dopaminergic signaling and predisposes to augmentation, rather than the drug depleting iron.

Counter-evidence held on record

"RLS patients often have low iron" (indication-linked, reverse causation) is not the same claim as "ropinirole depletes iron" (a drug-caused claim). The evidence assembled here supports only the former. No iron dose is recommended in this dossier; standard RLS iron-status checking (see Monitoring panel) is independent of ropinirole use and should not be attributed to the drug.

Limits on what this shows

• Why no grade: Both conditions in the ungraded test are met: no Tier B or Tier C source supports even a yellow grade, and no circulating claim exists to rebut as white.

Channels tried

PubMed search-listing pages, Europe PMC, Crossref, Semantic Scholar, DailyMed/FDA label full text, and general web search, across multiple phrasings: "ropinirole copper," "ropinirole ceruloplasmin," "dopamine agonist copper deficiency," "Parkinson's disease copper ceruloplasmin dopamine agonist treatment," and "pramipexole ropinirole trace mineral copper."

What was found instead

A body of Tier C literature exists on copper dyshomeostasis as a feature of Parkinson's disease itself (low blood copper as a disease-development comorbidity factor, altered ceruloplasmin ferroxidase activity, copper's role in alpha-synuclein aggregation). This describes disease pathophysiology, not a ropinirole treatment effect, and none of it proposes or tests a mechanism by which a D2/D3 agonist metabolized via CYP1A2 would alter copper handling, so it does not clear even the class-extrapolation bar for this drug. No drug-nutrient depletion guide, supplement retailer, or interaction checker (drugs.com) paired ropinirole with copper.

Genuine gap vs tooling-limited

Assessed as a genuine evidence gap. PubMed and PMC full-article pages repeatedly returned bot-verification/CAPTCHA challenges to this session's fetch tool during this review (a general access limitation, not specific to copper queries), and Crossref/Semantic Scholar search endpoints returned rate-limit (429) errors on some calls; however, general web search and publisher-hosted abstract pages remained accessible throughout and were used successfully across more than two independent phrasings for this category. A revision should still re-attempt the blocked PubMed/PMC/Semantic Scholar channels directly for copper before treating this gap as final.

Limits on what this shows

• Key negative/null findings: The effect was not ropinirole-specific: dopamine itself and pramipexole produced similar compositional shifts, with dopamine's effect weaker, attributed by the authors to more rapid metabolism. They interpret this as a class/motility-mediated effect, not a unique ropinirole chemical action.
• At-risk subgroups: Not established; the rats studied were healthy (non-Parkinson's, non-RLS), so relevance to already-dysbiotic patients is extrapolated, not measured.
• Counter-evidence: None identified; no study located shows gut microbiota composition preserved on ropinirole.

Regulatory status

FDA label documents ropinirole's own gastrointestinal adverse effects (nausea 40-60%, vomiting 11-12%, dyspepsia 10%, constipation 6% vs 3% in advanced Parkinson's) consistent with altered motility, but does not address microbiome composition.

Population evidence

van Kessel et al 2022 (mSystems): healthy, non-Parkinson's rats, 14-day dosing across three arms, dopamine, pramipexole plus levodopa-carbidopa, and ropinirole plus levodopa-carbidopa; carmine-red transit assay plus 16S rRNA sequencing of proximal small intestine and ileum.

Mechanism

Dopaminergic slowing of small-intestinal motility alters the luminal environment and selects for particular bacterial taxa (increased Lactobacillus and Bifidobacterium, decreased Lachnospiraceae and Prevotellaceae), rather than a direct antimicrobial drug effect.

Counter-evidence held on record

This is an animal, combination-therapy (levodopa-carbidopa co-administered), non-disease-state study. The direction of change is not established as harmful or beneficial in itself, only different from baseline, and must not be marketed as a "leaky gut" or dysbiosis-harm claim.

Limits on what this shows

• Key negative/null findings: Jost et al 1998 (n=12 de novo Parkinson's patients vs 27 controls): none showed a pathologic blood-pressure drop with ropinirole, and the standing noradrenaline rise was only modestly and non-significantly blunted (338 vs 425 pg/mL), substantially less than reported for ergot-derived agonists. Nimmons et al 2022 meta-analysis (21 RCTs, 3,783 patients) found dopamine agonists as a class carry no statistically significant increase in orthostatic hypotension risk versus placebo (OR 1.39, 95% CI 0.97-1.98); the single ropinirole-specific trial within that pool (n=393) showed 5% vs 2%, not significance-tested.
• At-risk subgroups: Elderly patients, the early dose-titration window, and co-prescription of antihypertensives. The RLS-dose population shows a much smaller signal than the higher-dose Parkinson's population.
• Counter-evidence: See the meta-analysis and physiologic-study null findings above; both directly weaken, without erasing, the FDA-label signal.

Regulatory status

FDA label §5.2: "Syncope, sometimes associated with bradycardia, was observed in association with treatment with ropinirole."

Population evidence

Early Parkinson's RCTs: syncope 12% (ropinirole) vs 1% (placebo). Advanced Parkinson's (with levodopa): 3% higher. RLS 12-week RCTs (n=496 ropinirole, n=500 placebo): orthostatic hypotension 0.8% vs 0.4% (FDA label §5.2, §5.3).

Mechanism

Dopaminergic D2/D3 agonism blunts peripheral sympathetic vasomotor tone and the noradrenergic response to standing, producing vasodepressor hypotension, particularly during dose escalation.

Counter-evidence held on record

This is the drug's own labeled autonomic/hemodynamic adverse effect, not a marker of anemia, low hemoglobin, or any nutrient status. No blood-oxygen-carrying marker (hemoglobin, hematocrit, ferritin) was measured in any source cited here, and this entry must never be used to suggest iron or B12 repletion.

Limits on what this shows

• Key negative/null findings: Neither study performed a direct ATP-yield or oxidative-phosphorylation-efficiency assay; "respiration ratio" is a coupling/efficiency proxy, not a direct ATP quantification, which limits how far this evidence generalizes to ATP production specifically.
• At-risk subgroups: Not applicable.
• Counter-evidence: No source identified shows ropinirole impairing ATP-generating capacity.

Regulatory status

Not addressed in FDA labeling.

Population evidence

None in humans. Parvez et al 2010 (isolated rat liver/brain mitochondria) and Andrabi et al 2020 (rat stroke model), the same two studies underlying the Mitochondrial burden entry above (see Overlap map).

Mechanism

Parvez 2010: ropinirole "does not impair normal mitochondrial respiration" at pore-blocking concentrations. Andrabi 2020: ropinirole treatment "restored respiration ratios" and preserved mitochondrial membrane potential after ischemia-reperfusion injury, alongside reduced infarct size and improved motor function.

Counter-evidence held on record

This evidence is indirect (respiration-ratio proxies in animal injury models) and must not be read as "ropinirole boosts energy" or ATP in ordinary clinical use. It only supports the absence of an ATP-depleting mechanism in the models tested.